logo
Share SHARE
FONT-SIZE Plus   Neg

Valeant Pharma, Actavis In Merger Talks : WSJ

Canadian drugmaker Valeant Pharmaceuticals International, Inc. (VRX,VRX.TO) is said to be in discussions to acquire rival Actavis Inc. (ACT) for over $13 billion, according to the Wall Street Journal.

While the companies were working towards an all-stock deal announcement, few Actavis' directors were against it around the middle of this week. But the executives on both sides are still working to resurrect the deal, the journal added.

In February, Valeant announced that it was in talks to make more acquisitions, and it remains open to discuss a potential "merger of equals". Actavis currently has a market value of nearly $13 billion.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of WPP Group Plc. were gaining around 6 percent in the morning trading on London after the advertising giant reported Wednesday positive current trading and expectations for increased results. This was after reporting higher headline profit and increased revenues in its first half, even as reported profit declined from last year. The company also announced a significant dividend growth. Athletic clothing company Under Armour has ended sponsorship of a female hunter after a video that showed her husband killing a bear caused an outrage. Sponsorship of Sarah Bowmar, the wife and hunting companion of US hunter Josh Bowmar, was dropped by Under Armor following the negative response to... The City of Somerville has decided not to appeal a key environmental permit granted in July for Wynn Resorts Ltd.'s $2.1 billion Everett casino project. The decision paves the way for work on the casino project, known as Wynn Boston Harbor, to go ahead.
comments powered by Disqus
Follow RTT